慢乙肝经治低病毒血症研究现状及中医药治疗优势展望

Research status of low-level viremia caused by chronic hepatitis B treatment and the prospect of traditional Chinese medicine treatment advantages

慢乙肝经治低病毒血症(LLV)是近年的热点问题,主要为慢乙肝患者经过抗病毒治疗后,仍会出现病毒的低复制状态。LLV患者始终存在发展为肝纤维化、肝硬化、肝癌、甚至其他终末期肝病的风险,严重威胁患者的生命健康。目前对于LLV患者尚无有力循证医学证据的治疗手段,同时缺乏相关的专家指南、共识等指导意见。中医药在慢乙肝的防治过程中始终发挥着独特的优势,因此,联合中医药治疗LLV患者具有广阔的前景及优势。本文将通过对目前LLV的研究进展进行阐述,并对联合中医药治疗LLV的优势及前景进行展望。

Low-level viremia(LLV)caused by chranic hepatitis B treatment is a hot issue in recent years,mainly because patients with chronic hepatitis B still have low virus replication after antiviral treatment.LLV patients always have the risk of developing liver fibrosis,liver cirrhosis,liver cancer and even other end-stage liver diseases,which seriously threatens the life and health of patients.At present,there is no strong evidence-based medical evidence treatment for LLV patients,and there is a lack of relevant expert guidelines,consensus and other guidance.Traditional Chinese medicine has always played a unique advantage in the prevention and treatment of chronic hepatitis B,therefore,the combination of traditional Chinese medicine in the treatment of LLV patients has broad prospects and advantages.This paper will elaborate the current research progress of LLV,and prospect the advantages and prospects of combined traditional Chinese medicine in the treatment of LLV.